We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Medtronic (MDT - Free Report) to post quarterly earnings of $1.23 per share in its upcoming report, which indicates no change from the year-ago quarter. Revenues are expected to be $8.37 billion, up 5.7% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Medtronic metrics that are commonly tracked and forecasted by Wall Street analysts.
The average prediction of analysts places 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' at $728.31 million. The estimate indicates a year-over-year change of +2.2%.
The combined assessment of analysts suggests that 'Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular' will likely reach $631.16 million. The estimate points to a change of +2.5% from the year-ago quarter.
Analysts predict that the 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' will reach $1.20 billion. The estimate points to a change of +5% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' should arrive at $490.80 million. The estimate suggests a change of +7.4% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- U.S. Revenue' of $4.26 billion. The estimate suggests a change of +4.3% year over year.
According to the collective judgment of analysts, 'Net Sales- U.S. Revenue- Medical Surgical' should come in at $886.66 million. The estimate points to a change of +0.6% from the year-ago quarter.
Analysts forecast 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' to reach $332.01 million. The estimate suggests a change of +6.4% year over year.
Analysts expect 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' to come in at $298.91 million. The estimate points to a change of +2.4% from the year-ago quarter.
The consensus estimate for 'Net Sales- ROW- Neuroscience- Specialty Therapies' stands at $326.25 million. The estimate indicates a year-over-year change of +3.9%.
The consensus among analysts is that 'Net Sales- ROW- Medical Surgical- Surgical & Endoscopy' will reach $960.12 million. The estimate indicates a change of +4.9% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- ROW- Cardiovascular' will reach $1.71 billion. The estimate suggests a change of +6.6% year over year.
Analysts' assessment points toward 'Net Sales- ROW- Cardiovascular- Coronary & Peripheral Vascular' reaching $363.10 million. The estimate indicates a year-over-year change of +4.6%.
Over the past month, Medtronic shares have recorded returns of +3.5% versus the Zacks S&P 500 composite's +3.5% change. Based on its Zacks Rank #3 (Hold), MDT will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics
Wall Street analysts expect Medtronic (MDT - Free Report) to post quarterly earnings of $1.23 per share in its upcoming report, which indicates no change from the year-ago quarter. Revenues are expected to be $8.37 billion, up 5.7% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Medtronic metrics that are commonly tracked and forecasted by Wall Street analysts.
The average prediction of analysts places 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' at $728.31 million. The estimate indicates a year-over-year change of +2.2%.
The combined assessment of analysts suggests that 'Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular' will likely reach $631.16 million. The estimate points to a change of +2.5% from the year-ago quarter.
Analysts predict that the 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' will reach $1.20 billion. The estimate points to a change of +5% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' should arrive at $490.80 million. The estimate suggests a change of +7.4% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- U.S. Revenue' of $4.26 billion. The estimate suggests a change of +4.3% year over year.
According to the collective judgment of analysts, 'Net Sales- U.S. Revenue- Medical Surgical' should come in at $886.66 million. The estimate points to a change of +0.6% from the year-ago quarter.
Analysts forecast 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' to reach $332.01 million. The estimate suggests a change of +6.4% year over year.
Analysts expect 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' to come in at $298.91 million. The estimate points to a change of +2.4% from the year-ago quarter.
The consensus estimate for 'Net Sales- ROW- Neuroscience- Specialty Therapies' stands at $326.25 million. The estimate indicates a year-over-year change of +3.9%.
The consensus among analysts is that 'Net Sales- ROW- Medical Surgical- Surgical & Endoscopy' will reach $960.12 million. The estimate indicates a change of +4.9% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- ROW- Cardiovascular' will reach $1.71 billion. The estimate suggests a change of +6.6% year over year.
Analysts' assessment points toward 'Net Sales- ROW- Cardiovascular- Coronary & Peripheral Vascular' reaching $363.10 million. The estimate indicates a year-over-year change of +4.6%.
View all Key Company Metrics for Medtronic here>>>Over the past month, Medtronic shares have recorded returns of +3.5% versus the Zacks S&P 500 composite's +3.5% change. Based on its Zacks Rank #3 (Hold), MDT will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .